Digital Biomarkers Market

Industry Overview

The digital biomarkers market refers to the use of digital technologies, such as wearable devices, sensors, and mobile applications, to collect and analyze physiological, behavioral, and environmental data in order to assess an individual's health or monitor the progression of a disease. The global digital biomarkers market was valued at USD 0.86 billion in 2022 and is anticipated to be valued at USD 5.4 billion by 2030, growing at a significant CAGR of 22.5% during the forecast period 2023-2030. A biomarker is an objective measure that captures physiological, pathological, or anatomical features of a person in order to understand the state of being and, specifically, an alert system of the body. The rapid growth of digital tools like smartphones and wearables across the world helps in the faster collecting of health information by these devices and also includes information collected by digital biomarkers. The digital biomarkers are of great help for the patient suffering from chronic diseases as these digital biomarkers help to monitor the patient’s condition regularly and provide quality care.  

Moreover, it helps the doctor to measure and track symptoms of the patient so as to prevent the progression of irreversible diseases like Parkinson&rsquo's and Alzheimer&rsquo's. Also, digital biomarkers are used in various applications for clinical trials and clinical care.

The COVID-19 pandemic is adopting digital biomarkers to expedite the screening and diagnosis of COVID-19 patients remotely. For instance, the National Institutes of Health (NIH) has developed physIQ by advancing and validating an algorithm, that can use existing wearable biosensor-derived analytics to discover a novel digital biomarker for COVID-19-associated decompensation.

Market Segmentation

Insight by System Component

Based on system component, the global digital biomarkers are segmented into data collection tools and data integration systems. The data collection tools are further segmented into digital platforms, mobile apps, desktop-based software, wearable, and biosensors. The proliferation of digital tools like wearables and smartphones globally which increase the health information collected by these devices. Moreover, digital biomarkers are used to treat patients suffering from chronic diseases.  Moreover, less cost and enhanced scalability of digital biomarkers in the smartphone apps will help in providing social, behavioral, psychological and environmental data which was inaccessible formerly.

Insight by Therapeutic Area

Based on therapeutic area, the global digital biomarkers are divided into cardiovascular diseases, neurodegenerative disorders, sleep and movement diseases, psychiatric disorders, chronic pain, gastrointestinal diseases, diabetes, respiratory diseases, and others.  Among the segments, cardiovascular disease holds the largest share in 2020 as digital biomarkers provides in-depth insights in the cardiac patient’s response during standardized activity and improve cardiac rehabilitation outcome. Moreover, chronic pain is anticipated to witness the fastest growth during the forecast period 2023-2030 owing to the advancement and adoption of AR and VR solution in detection and treatment of chronic pain.

Insight by Application

Based on application, the global digital biomarkers market is divided into wellness, disease diagnosis, personalized medication, and drug discovery and development. The drug discovery and development is growing at a significant pace owing to the rising adoption of AI and cloud-based services for efficient and cost-effective drug discovery in the pharmaceutical industry.

Insight by Development Status

Based on development status, the global digital biomarkers market is categorized into novel digital biomarkers, original digital biomarkers, and approved digital biomarkers. Among the segments, approved digital biomarkers is anticipated to witness the largest revenue in the market owing to its reliability and are legally authentic as it is FDA approved.

Insight by End-User

Based on end-user, the global digital biomarkers market is divided into pharmaceutical companies & labs, healthcare providers, and insurance payers.  Pharmaceutical companies is anticipated to have the highest share owing to the development of drugs resulted in the generation of novel data from the digital biomarkers diagnostics. This will researchers to understand the progression of the disease and know the performance of the patients towards the drugs. Thus, helping pharmaceutical companies to develop tailored drugs according to patient’s specification, resulting in the growth of the global digital biomarkers market.

Global Digital Biomarkers Market Report Coverage

Industry Dynamics

Industry Trends

The adoption of high-speed networks like 3G and 4G, development in information technology along with rising demand for solutions that helps in efficiently reducing the healthcare cost and treat chronically ill patients are the trends for the development digital solutions for biomarkers.  

Wearable Devices: The popularity of wearable devices, such as smartwatches, fitness trackers, and medical-grade wearables, has surged in recent years. These devices can collect a wide range of data, including heart rate, activity levels, sleep patterns, and more, providing valuable information for health monitoring and disease management.

Remote Patient Monitoring: The COVID-19 pandemic has accelerated the adoption of remote patient monitoring solutions. Digital biomarkers enable healthcare providers to remotely monitor patients' vital signs, symptoms, and other health parameters, reducing the need for in-person visits and improving patient outcomes.

Chronic Disease Management: Digital biomarkers play a crucial role in managing chronic diseases, such as diabetes, cardiovascular diseases, and respiratory conditions. By continuously monitoring relevant parameters, healthcare providers can detect early signs of deterioration, adjust treatment plans, and provide timely interventions, leading to better disease management and improved patient outcomes.
 

Growth Drivers

Factors driving the growth of the global digital biomarkers can be attributed to the rising adoption of connected digital devices, heath related mobile applications, rising smartphone penetration, rising number of industry players, and emergence of wearable devices. Moreover, significant product launch, favorable government initiatives, FDA approval, failure of drugs for neurodegenerative disorders requires alternatives, increasing cases of health issues such as mental health problems, diabetes, BP, cardiovascular diseases, etc.  will propel the growth of the global digital biomarkers market. The cost of developing a drug is increasing owing to extensive R&D involved as a result biomarker will target the avenues where research needs to be focused, resulting in decreasing the number of processes which in turn will reduce the cost.

Drug Development and Clinical Trials: Pharmaceutical companies are increasingly utilizing digital biomarkers in drug development and clinical trials. These biomarkers can help assess the safety and efficacy of new therapies, identify patient subgroups for targeted treatments, and provide objective measures for evaluating treatment outcomes.

Data Analytics and Artificial Intelligence: The availability of large datasets and advancements in data analytics and artificial intelligence (AI) technologies have significantly enhanced the potential of digital biomarkers. AI algorithms can analyze complex datasets, identify patterns, and generate predictive models, enabling more accurate and personalized health assessments.

Challenges

However, the digital biomarkers market also faces several challenges, including data privacy concerns, regulatory hurdles, and the need for robust validation and standardization processes. Additionally, the integration of digital biomarkers into clinical practice and healthcare systems requires careful planning and coordination.

Opportunities

The digital biomarkers market is expected to continue growing as the demand for personalized and data-driven healthcare solutions increases. The market holds immense potential for improving healthcare outcomes, enabling early disease detection, and empowering individuals to take control of their health and well-being. The advent of personalized medicine, huge investment in voice-based digital biomarkers and investment in wearable technology are the opportunities prevalent in the global digital biomarkers market.

Geographic Overview

North America is anticipated to hold the largest market in the digital biomarkers market owing to strong presence of leading industry players, rising investment in R&D, rising product launches, and increasing approval of smart devices in the region.  Asia Pacific is projected to grow at a faster pace owing to the increasing emphasis by government on enhancing healthcare infrastructure, increasing adoption of smart devices, increasing incidences of COVID-19 outbreak, and presence of many patients having chronic diseases in the region.

Competitive Insight

The industry Players are focusing on R&D in the product development and wants to build their brand value. Various other strategies such as mergers and acquisitions, collaborating with research and medical institutions, and expanding their presence in the digital biomarkers market.

FDA cleared two AI-enabled wearable devices, specifically designed to monitor patient's vital signs. KardiaMobile, by AliveCor, is the first device to have received FDA clearance. It detects three of the most common heart arrythmias.

Some of the key players operating in the global digital biomarkers market: AliveCor Labs, Eli Lilly and Company, Biogen, Novartis AG, Fitbit LLC, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Pfizer Inc., and Takeda Pharmaceutical Company Limited.

The Digital Biomarkers Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2023–2030.

Segments Covered in the Report

• By System Component
  • Data Collection Tools
    • Digital Platforms
    • Mobile Apps
    • Desktop-Based Software
    • Wearable
    • Biosensors
  • Data Integration Systems
• By Therapeutic Area
  • Cardiovascular Diseases
  • Neurodegenerative Disorders
  • Sleep and Movement Diseases
  • Psychiatric Disorders
  • Chronic Pain
  • Gastrointestinal Diseases
  • Diabetes
  • Respiratory Diseases
  • Others
• By Application
  • Wellness
  • Disease Diagnosis
  • Personalized Medication
  • Drug Discovery and Development
• By Development Status
  • Novel Digital Biomarkers
  • Original Digital Biomarkers
  • Approved Digital Biomarkers
• By End-User
  • Pharmaceutical Companies & Labs
  • Healthcare Providers
  • Insurance Payers

Region Covered in the Report

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World (RoW)
  • Brazil
  • Saudi Arabia
  • South Africa
  • U.A.E.
  • Other Countries

Source: VynZ Research

Source: VynZ Research

1.    Research Overview

        1.1.    The Report Offers
        1.2.    Market Coverage
                1.2.1.    By System Component
                1.2.2.    By Therapeutic Area
                1.2.3.    By Application
                1.2.4.    By Development Status
                1.2.5.    By End-User
                1.2.6.    By Region
        1.3.    Research Phases
        1.4.    Limitations
        1.5.    Market Methodology
                1.5.1.    Data Sources
                        1.5.1.1. Primary Research
                        1.5.1.2. Secondary Research
                1.5.2.    Methodology
                        1.5.2.1. Data Exploration
                        1.5.2.2. Forecast Parameters
                        1.5.2.3. Data Validation
                        1.5.2.4. Assumptions
                1.5.3.    Study Period & Data Reporting Unit

2.    Executive Summary

3.    Industry Overview

        3.1.    Industry Dynamics
                3.1.1.    Market Growth Drivers
                3.1.2.    Market Restraints
                3.1.3.    Key Market Trends
                3.1.4.    Major Opportunities
        3.2.    Industry Ecosystem
                3.2.1.    Porter’s Five Forces Analysis
                3.2.2.    Recent Development Analysis
                3.2.3.    Value Chain Analysis
        3.3.    Competitive Insight
                3.3.1.    Competitive Position of Industry Players
                3.3.2.    Market Attractive Analysis
                3.3.3.    Market Share Analysis

4.    Global Market Estimate and Forecast

        4.1.    Global Market Overview
        4.2.    Global Market Estimate and Forecast to 2030

5.    Market Segmentation Estimate and Forecast

        5.1.    By System Component
                5.1.1.    Data Collection Tools 
                        5.1.1.1. Market Definition
                        5.1.1.2. Market Estimation and Forecast to 2030  
                                5.1.1.2.1. Digital Platforms
                                5.1.1.2.2. Mobile Apps
                                5.1.1.2.3. Desktop-Based Software
                                5.1.1.2.4. Wearable
                                5.1.1.2.5. Biosensors
                5.1.2.    Data Integration Systems
                        5.1.2.1. Market Definition
                        5.1.2.2. Market Estimation and Forecast to 2030
        5.2.    By Therapeutic Area
                5.2.1.    Cardiovascular Diseases
                        5.2.1.1. Market Definition
                        5.2.1.2. Market Estimation and Forecast to 2030
                5.2.2.    Neurodegenerative Disorders
                        5.2.2.1. Market Definition
                        5.2.2.2. Market Estimation and Forecast to 2030
                5.2.3.    Sleep and Movement Diseases
                        5.2.3.1. Market Definition
                        5.2.3.2. Market Estimation and Forecast to 2030
                5.2.4.    Psychiatric Disorders
                        5.2.4.1. Market Definition
                        5.2.4.2. Market Estimation and Forecast to 2030
                5.2.5.    Chronic Pain
                        5.2.5.1. Market Definition
                        5.2.5.2. Market Estimation and Forecast to 2030
                5.2.6.    Gastrointestinal Diseases
                        5.2.6.1. Market Definition
                        5.2.6.2. Market Estimation and Forecast to 2030
                5.2.7.    Diabetes
                        5.2.7.1. Market Definition
                        5.2.7.2. Market Estimation and Forecast to 2030
                5.2.8.    Respiratory Diseases
                        5.2.8.1. Market Definition
                        5.2.8.2. Market Estimation and Forecast to 2030
                5.2.9.    Others
                        5.2..1. Market Definition
                        5.2.9.2. Market Estimation and Forecast to 2030
        5.3.    By Application   
                5.3.1.    Wellness
                        5.3.1.1. Market Definition
                        5.3.1.2. Market Estimation and Forecast to 2030
                5.3.2.    Disease Diagnosis
                        5.3.2.1. Market Definition
                        5.3.2.2. Market Estimation and Forecast to 2030
                5.3.3.    Personalized Medication
                        5.3.3.1. Market Definition
                        5.3.3.2. Market Estimation and Forecast to 2030
                5.3.4.    Drug Discovery and Development
                        5.3.4.1. Market Definition
                        5.3.4.2. Market Estimation and Forecast to 2030
        5.4.    By Development Status
                5.4.1.    Novel Digital Biomarkers
                        5.4.1.1. Market Definition
                        5.4.1.2. Market Estimation and Forecast to 2030
                5.4.2.    Original Digital Biomarkers
                        5.4.2.1. Market Definition
                        5.4.2.2. Market Estimation and Forecast to 2030
                5.4.3.    Approved Digital Biomarkers
                        5.4.3.1. Market Definition
                        5.4.3.2. Market Estimation and Forecast to 2030
        5.5.    By End-User
                5.5.1.    Pharmaceutical Companies & Labs
                        5.5.1.1. Market Definition
                        5.5.1.2. Market Estimation and Forecast to 2030
                5.5.2.    Healthcare Providers
                        5.5.2.1. Market Definition
                        5.5.2.2. Market Estimation and Forecast to 2030
                5.5.3.    Insurance Payers
                        5.5.3.1. Market Definition
                        5.5.3.2. Market Estimation and Forecast to 2030

6.    North America Market Estimate and Forecast

        6.1.    By System Component
        6.2.    By Therapeutic Area
        6.3.    By Application
        6.4.    By Development Status
        6.5.    By End-User
        6.6.    By Country
                6.6.1.    U.S. Market Estimate and Forecast
                6.6.2.    Canada Market Estimate and Forecast
                6.6.3.    Mexico Market Estimate and Forecast

7.    Europe Market Estimate and Forecast

        7.1.    By System Component
        7.2.    By Therapeutic Area 
        7.3.    By Application
        7.4.    By Development Status
        7.5.    By End-User
        7.6.    By Country
                7.6.1.    Germany Market Estimate and Forecast
                7.6.2.    France Market Estimate and Forecast
                7.6.3.    U.K. Market Estimate and Forecast
                7.6.4.    Italy Market Estimate and Forecast
                7.6.5.    Spain Market Estimate and Forecast
                7.6.6.    Rest of Europe Market Estimate and Forecast

8.    Asia-Pacific Market Estimate and Forecast

        8.1.    By System Component
        8.2.    By Therapeutic Area 
        8.3.    By Application
        8.4.    By Development Status
        8.5.    By End-User
        8.6.    By Country
                8.6.1.    China Market Estimate and Forecast
                8.6.2.    Japan Market Estimate and Forecast
                8.6.3.    India Market Estimate and Forecast
                8.6.4.    South Korea Market Estimate and Forecast
                8.6.5.    Singapore Market Estimate and Forecast
                8.6.6.    Rest of Asia-Pacific Market Estimate and Forecast

9.    Rest of the World (RoW) Market Estimate and Forecast

        9.1.    By System Component
        9.2.    By Therapeutic Area 
        9.3.    By Application
        9.4.    By Development Status
        9.5.    By End-User
        9.6.    By Country
                9.6.1.    Brazil Market Estimate and Forecast
                9.6.2.    Saudi Arabia Market Estimate and Forecast
                9.6.3.    South Africa Market Estimate and Forecast
                9.6.4.    Other Countries Market Estimate and Forecast

10.    Company Profiles

        10.1.    AliveCor Labs
                10.1.1.    Snapshot
                10.1.2.    Overview
                10.1.3.    Offerings
                10.1.4.    Financial Insight
                10.1.5.    Recent Developments
        10.2.    Eli Lilly and Company
                10.2.1.    Snapshot
                10.2.2.    Overview
                10.2.3.    Offerings
                10.2.4.    Financial Insight
                10.2.5.    Recent Developments
        10.3.    Biogen
                10.3.1.    Snapshot
                10.3.2.    Overview
                10.3.3.    Offerings
                10.3.4.    Financial Insight
                10.3.5.    Recent Developments
        10.4.    Novartis AG
                10.4.1.    Snapshot
                10.4.2.    Overview
                10.4.3.    Offerings
                10.4.4.    Financial Insight
                10.4.5.    Recent Developments
        10.5.    Fitbit LLC
                10.5.1.    Snapshot
                10.5.2.    Overview
                10.5.3.    Offerings
                10.5.4.    Financial Insight
                10.5.5.    Recent Developments
        10.6.    GlaxoSmithKline plc
                10.6.1.    Snapshot
                10.6.2.    Overview
                10.6.3.    Offerings
                10.6.4.    Financial Insight
                10.6.5.    Recent Developments
        10.7.    F. Hoffmann-La Roche Ltd
                10.7.1.    Snapshot
                10.7.2.    Overview
                10.7.3.    Offerings
                10.7.4.    Financial Insight
                10.7.5.    Recent Developments
        10.8.    Koninklijke Philips N.V.
                10.8.1.    Snapshot
                10.8.2.    Overview
                10.8.3.    Offerings
                10.8.4.    Financial Insight
                10.8.5.    Recent Developments
        10.9.    Pfizer Inc.
                10.9.1.    Snapshot
                10.9.2.    Overview
                10.9.3.    Offerings
                10.9.4.    Financial Insight
                10.9.5.    Recent Developments
        10.10.    Takeda Pharmaceutical Company Limited
                10.10.1. Snapshot
                10.10.2. Overview
                10.10.3. Offerings
                10.10.4. Financial Insight
                10.10.5. Recent Developments

11.    Appendix

        11.1.    Exchange Rates
        11.2.    Abbreviations

Note: Financial insight and recent developments of different companies are subject to availability of information in secondary domain.

List of Tables

Table 1 Sources
Table 2 Study Periods
Table 3 Data Reporting Unit
Table 4 Global Digital Biomarkers Market Size, By System Component, 2018-2022 (USD Billion)
Table 5 Global Digital Biomarkers Market Size, By System Component, 2023–2030 (USD Billion)
Table 6 Global Digital Biomarkers Market Size, By Therapeutic Area, 2018-2022 (USD Billion)
Table 7 Global Digital Biomarkers Market Size, By Therapeutic Area, 2023–2030 (USD Billion)
Table 8 Global Digital Biomarkers Market Size, By Application, 2018-2022 (USD Billion)
Table 9 Global Digital Biomarkers Market Size, By Application, 2023–2030 (USD Billion)
Table 10 Global Digital Biomarkers Market Size, By Development Status, 2018-2022 (USD Billion)
Table 11 Global Digital Biomarkers Market Size, By Development Status, 2023–2030 (USD Billion)
Table 12 Global Digital Biomarkers Market Size, By End-User, 2018-2022 (USD Billion)
Table 13 Global Digital Biomarkers Market Size, By End-User, 2023–2030 (USD Billion)
Table 14 Global Digital Biomarkers Market Size, by Region, 2018-2022 (USD Billion)
Table 15 Global Digital Biomarkers Market Size, by Region, 2023–2030 (USD Billion)
Table 16 North America Digital Biomarkers Market Size, By System Component, 2018-2022 (USD Billion)
Table 17 North America Digital Biomarkers Market Size, By System Component, 2023–2030 (USD Billion)
Table 18 North America Digital Biomarkers Market Size, By Therapeutic Area, 2018-2022 (USD Billion)
Table 19 North America Digital Biomarkers Market Size, By Therapeutic Area, 2023–2030 (USD Billion)
Table 20 North America Digital Biomarkers Market Size, By Application, 2018-2022 (USD Billion)
Table 21 North America Digital Biomarkers Market Size, By Application, 2023–2030 (USD Billion)
Table 22 North America Digital Biomarkers Market Size, By Development Status, 2018-2022 (USD Billion)
Table 23 North America Digital Biomarkers Market Size, By Development Status, 2023–2030 (USD Billion)
Table 24 North America Digital Biomarkers Market Size, By End-User, 2018-2022 (USD Billion)
Table 25 North America Digital Biomarkers Market Size, By End-User, 2023–2030 (USD Billion)
Table 26 North America Digital Biomarkers Market Size, by Region, 2018-2022 (USD Billion)
Table 27 North America Digital Biomarkers Market Size, by Region, 2023–2030 (USD Billion)
Table 28 Europe Digital Biomarkers Market Size, By System Component, 2018-2022 (USD Billion)
Table 29 Europe Digital Biomarkers Market Size, By System Component, 2023–2030 (USD Billion)
Table 30 Europe Digital Biomarkers Market Size, By Therapeutic Area, 2018-2022 (USD Billion)
Table 31 Europe Digital Biomarkers Market Size, By Therapeutic Area, 2023–2030 (USD Billion)
Table 32 Europe Digital Biomarkers Market Size, By Application, 2018-2022 (USD Billion)
Table 33 Europe Digital Biomarkers Market Size, By Application, 2023–2030 (USD Billion)
Table 34 Europe Digital Biomarkers Market Size, By Development Status, 2018-2022 (USD Billion)
Table 35 Europe Digital Biomarkers Market Size, By Development Status, 2023–2030 (USD Billion)
Table 36 Europe Digital Biomarkers Market Size, By End-User, 2018-2022 (USD Billion)
Table 37 Europe Digital Biomarkers Market Size, By End-User, 2023–2030 (USD Billion)
Table 38 Europe Digital Biomarkers Market Size, by Region, 2018-2022 (USD Billion)
Table 39 Europe Digital Biomarkers Market Size, by Region, 2023–2030 (USD Billion)
Table 40 Asia-Pacific Digital Biomarkers Market Size, By System Component, 2018-2022 (USD Billion)
Table 41 Asia-Pacific Digital Biomarkers Market Size, By System Component, 2023–2030 (USD Billion)
Table 42 Asia-Pacific Digital Biomarkers Market Size, By Therapeutic Area, 2018-2022 (USD Billion)
Table 43 Asia-Pacific Digital Biomarkers Market Size, By Therapeutic Area, 2023–2030 (USD Billion)
Table 44 Asia-Pacific Digital Biomarkers Market Size, By Application, 2018-2022 (USD Billion)
Table 45 Asia-Pacific Digital Biomarkers Market Size, By Application, 2023–2030 (USD Billion)
Table 46 Asia-Pacific Digital Biomarkers Market Size, By Development Status, 2018-2022 (USD Billion)
Table 47 Asia-Pacific Digital Biomarkers Market Size, By Development Status, 2023–2030 (USD Billion)
Table 48 Asia-Pacific Digital Biomarkers Market Size, By End-User, 2018-2022 (USD Billion)
Table 49 Asia-Pacific Digital Biomarkers Market Size, By End-User, 2023–2030 (USD Billion)
Table 50 Asia-Pacific Digital Biomarkers Market Size, by Region, 2018-2022 (USD Billion)
Table 51 Asia-Pacific Digital Biomarkers Market Size, by Region, 2023–2030 (USD Billion)
Table 52 RoW Digital Biomarkers Market Size, By System Component, 2018-2022 (USD Billion)
Table 53 RoW Digital Biomarkers Market Size, By System Component, 2023–2030 (USD Billion)
Table 54 RoW Digital Biomarkers Market Size, By Therapeutic Area, 2018-2022 (USD Billion)
Table 55 RoW Digital Biomarkers Market Size, By Therapeutic Area, 2023–2030 (USD Billion)
Table 56 RoW Digital Biomarkers Market Size, By Application, 2018-2022 (USD Billion)
Table 57 RoW Digital Biomarkers Market Size, By Application, 2023–2030 (USD Billion)
Table 58 RoW Digital Biomarkers Market Size, By Development Status, 2018-2022 (USD Billion)
Table 59 RoW Digital Biomarkers Market Size, By Development Status, 2023–2030 (USD Billion)
Table 60 RoW Digital Biomarkers Market Size, By End-User, 2018-2022 (USD Billion)
Table 61 RoW Digital Biomarkers Market Size, By End-User, 2023–2030 (USD Billion)
Table 62 RoW Digital Biomarkers Market Size, by Region, 2018-2022 (USD Billion)
Table 63 RoW Digital Biomarkers Market Size, by Region, 2023–2030 (USD Billion)
Table 64 Snapshot – AliveCor Labs
Table 65 Snapshot – Eli Lilly and Company
Table 66 Snapshot – Biogen
Table 67 Snapshot – Novartis AG
Table 68 Snapshot – Fitbit LLC
Table 69 Snapshot – GlaxoSmithKline plc
Table 70 Snapshot – F. Hoffmann-La Roche Ltd
Table 71 Snapshot – Koninklijke Philips N.V.
Table 72 Snapshot – Pfizer Inc.
Table 73 Snapshot – Takeda Pharmaceutical Company Limited

List of Figures

Figure 1 Market Coverage
Figure 2 Research Phases
Figure 3 Secondary Sources for Different Parameters
Figure 4 Methodology
Figure 5 Data Mining & Exploration
Figure 6 Data Triangulation
Figure 7 Assumptions for Market Estimation and Forecast
Figure 8 Market Synopsis
Figure 9 Global Digital Biomarkers Market - Growth Drivers and Restraints
Figure 10 Competitive Benchmark
Figure 11 Global Digital Biomarkers Market Highlight
Figure 12 Global Digital Biomarkers Market Size, By System Component,  2018–2030(USD Billion)
Figure 13 Global Digital Biomarkers Market Size, By Therapeutic Area,  2018–2030(USD Billion)
Figure 14 Global Digital Biomarkers Market Size, By Application,  2018–2030(USD Billion)
Figure 15 Global Digital Biomarkers Market Size, By Development Status,  2018–2030(USD Billion)
Figure 16 Global Digital Biomarkers Market Size, By End-User,  2018–2030(USD Billion)
Figure 17 Global Digital Biomarkers Market Size, by Region,  2018–2030(USD Billion)
Figure 18 North America Digital Biomarkers Market Highlight
Figure 19 North America Digital Biomarkers Market Size, By System Component,  2018–2030(USD Billion)
Figure 20 North America Digital Biomarkers Market Size, By Therapeutic Area,  2018–2030(USD Billion)
Figure 21 North America Digital Biomarkers Market Size, By Application,  2018–2030(USD Billion)
Figure 22 North America Digital Biomarkers Market Size, By Development Status,  2018–2030(USD Billion)
Figure 23 North America Digital Biomarkers Market Size, By End-User,  2018–2030(USD Billion)
Figure 24 North America Digital Biomarkers Market Size, by Region,  2018–2030(USD Billion)
Figure 25 Europe Digital Biomarkers Market Highlight
Figure 26 Europe Digital Biomarkers Market Size, By System Component,  2018–2030(USD Billion)
Figure 27 Europe Digital Biomarkers Market Size, By Therapeutic Area,  2018–2030(USD Billion)
Figure 28 Europe Digital Biomarkers Market Size, By Application,  2018–2030(USD Billion)
Figure 29 Europe Digital Biomarkers Market Size, By Development Status,  2018–2030(USD Billion)
Figure 30 Europe Digital Biomarkers Market Size, By End-User,  2018–2030(USD Billion)
Figure 31 Europe Digital Biomarkers Market Size, by Region,  2018–2030(USD Billion)
Figure 34 Asia-Pacific Digital Biomarkers Market Highlight
Figure 35 Asia-Pacific Digital Biomarkers Market Size, By System Component,  2018–2030(USD Billion)
Figure 36 Asia-Pacific Digital Biomarkers Market Size, By Therapeutic Area,  2018–2030(USD Billion)
Figure 37 Asia-Pacific Digital Biomarkers Market Size, By Application,  2018–2030(USD Billion)
Figure 38 Asia-Pacific Digital Biomarkers Market Size, By Development Status,  2018–2030(USD Billion)
Figure 39 Asia-Pacific Digital Biomarkers Market Size, By End-User,  2018–2030(USD Billion)
Figure 40 Asia-Pacific Digital Biomarkers Market Size, by Region,  2018–2030(USD Billion)
Figure 41 RoW Digital Biomarkers Market Highlight
Figure 42 RoW Digital Biomarkers Market Size, By System Component,  2018–2030(USD Billion)
Figure 43 RoW Digital Biomarkers Market Size, By Therapeutic Area,  2018–2030(USD Billion)
Figure 44 RoW Digital Biomarkers Market Size, By Application,  2018–2030(USD Billion)
Figure 45 RoW Digital Biomarkers Market Size, By Development Status,  2018–2030(USD Billion)
Figure 46 RoW Digital Biomarkers Market Size, By End-User,  2018–2030(USD Billion)
Figure 47 RoW Digital Biomarkers Market Size, by Region,  2018–2030(USD Billion)